Mediators of the effect of ertugliflozin on a composite kidney outcome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: analyses from VERTIS CV

被引：0

作者：

Cherney, D. Z. I. ^{[1
]}

Segar, M. ^{[2
]}

Pandey, A. ^{[2
]}

Cannon, C. P. ^{[3
]}

Cosentino, F. ^{[4
,5
]}

Dagogo-Jack, S. ^{[6
]}

Pratley, R. E. ^{[7
]}

Frederich, R. ^{[8
]}

Cater, N. B. ^{[9
]}

Maldonado, M. ^{[10
,11
]}

Liu, J. ^{[11
]}

Liu, C. -C. ^{[11
]}

Pong, A. ^{[11
]}

McGuire, D. K. ^{[12
]}

机构：

[1] Univ Toronto, Div Nephrol, Toronto, ON, Canada

[2] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[3] Harvard Med Sch, Brigham & Womens Hosp, Cardiovasc Div, Boston, MA 02115 USA

[4] Karolinska Inst, Stockholm, Sweden

[5] Karolinska Univ Hosp Solna, Stockholm, Sweden

[6] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA

[7] AdventHlth Translat Res Inst, Memphis, TN USA

[8] Pfizer Inc, Collegeville, PA USA

[9] Pfizer Inc, New York, NY USA

[10] Merck Sharp & Dohme Ltd, London, England

[11] Merck Co Inc, Kenilworth, NJ USA

[12] Univ Texas Southwestern Med Ctr Dallas, Parkland Hosp & Hlth Syst, Dallas, TX 75390 USA

来源：

EUROPEAN HEART JOURNAL | 2021年 / 42卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2925 / 2925

页数：1

共 50 条

[1] Mediation analyses of the effect of ertugliflozin on hospitalisation for heart failure in patients with type 2 diabetes and atherosclerotic cardiovascular disease from the VERTIS CV trial
Segar, M. W.
Pandey, A.
Cherney, D. Z. I.
Cannon, C. P.
Cosentino, F.
Dagogo-Jack, S.
Pratley, R. E.
Shih, W. J.
Frederich, R.
Cater, N. B.
Maldonado, M.
Liu, J.
Liu, C.
Pong, A.
McGuire, D. K.
[J]. EUROPEAN HEART JOURNAL, 2021, 42 : 2649 - 2649
[2] Ertugliflozin in older patients with type 2 diabetes: an analysis from VERTIS CV
Pratley, R. E.
Cannon, C. P.
Charbonnel, B.
Cherney, D. Z. I.
Cosentino, F.
McGuire, D. K.
Shih, W. J.
Essex, M. N.
Lawrence, D.
Jones, P. L. S.
Liu, J.
Adamsons, I. A.
Dagogo-Jack, S.
[J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 30 - 31
[3] Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial
Odutayo, Ayodele
Cosentino, Francesco
Pratley, Richard E.
Dagogo-Jack, Samuel
McGuire, Darren K.
Frederich, Robert
Fu, Wei
Cannon, Christopher P.
Cherney, David Z. I.
[J]. DIABETES OBESITY & METABOLISM, 2024, 26 (08): : 3478 - 3481
[4] Eligibility for Icosapent Ethyl in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: An Analysis of VERTIS CV
Kim, Joseph M.
Bhatt, Deepak L.
Dagogo-Jack, Samuel
Cherney, David
Cosentino, Francesco
McGuire, Darren K.
Pratley, Richard E.
Liu, Chih-Chin
Cater, Nilo B.
Frederich, Robert
Mancuso, James P.
Cannon, Christopher P.
[J]. DIABETES, 2022, 71
[5] Sustained weight loss with ertugliflozin in patients with T2D and atherosclerotic cardiovascular disease in VERTIS CV
Cosentino, F.
Dagogo-Jack, S.
Frederich, R.
Cannon, C. P.
Cherney, D. Z. I.
Mancuso, J. P.
Wynant, W.
Liu, J.
Cater, N. B.
Pratley, R. E.
[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 197
[6] Glycaemic efficacy and safety of ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from VERTIS CV
Dagogo-Jack, S.
Pratley, R. E.
Cherney, D. Z. I.
Charbonnel, B.
McGuire, D. K.
Cosentino, F.
Shih, W. J.
Liu, J.
Frederich, R.
Mancuso, J. P.
Raji, A.
Gantz, I.
[J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 225 - 226
[7] HYPOGLYCEMIA AND CV OUTCOMES IN PARTICIPANTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: OBSERVATIONS FROM THE VERTIS CV TRIAL
Pratley, Richard E.
McGuire, Darren K.
Fu, Wei
Cannon, Christopher P.
Cherney, David Z. I.
Cosentino, Francesco
Liu, Jie
Frederich, Robert
Mancuso, James P.
Dagogo-Jack, Samuel
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 2062 - 2062
[8] Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial
Cosentino, Francesco
Cannon, Christopher P.
Cherney, David Z. I.
Masiukiewicz, Urszula
Pratley, Richard
Dagogo-Jack, Sam
Frederich, Robert
Charbonnel, Bernard
Mancuso, James
Shih, Weichung J.
Terra, Steven G.
Cater, Nilo B.
Gantz, Ira
McGuire, Darren K.
[J]. CIRCULATION, 2020, 142 (23) : 2205 - 2215
[9] Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy
Lingvay, Ildiko
Greenberg, Michelle
Gallo, Silvina
Shi, Harry
Liu, Jie
Gantz, Ira
[J]. DIABETES OBESITY & METABOLISM, 2021, 23 (07): : 1640 - 1651
[10] Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV
Dagogo-Jack, Samuel
Frederich, Robert
Liu, Jie
Cannon, Christopher P.
Shi, Harry
Cherney, David Z., I
Cosentino, Francesco
Masiukiewicz, Urszula
Gantz, Ira
Pratley, Richard E.
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (08): : 2042 - 2051

← 1 2 3 4 5 →